Phase 1Completed

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

A Phase 1, 6-part, Open-label, Fixed-sequence Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Single-dose Pharmacokinetics of KarXT and Effects of KarXT on the Single-dose Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company (Industry)
Enrollment
133 enrolled
Conditions
Healthy Volunteers
Interventions
Xanomeline/Trospium Chloride; Lithium; Valproic Acid; Lamotrigine
Ages
adults, older adults
Registry
NCT06729970

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to evaluate the effects of lithium, valproic acid, and lamotrigine on the single-dose pharmacokinetics (PK) of KarXT and the effect of KarXT on the single-dose PK of lithium, valproic acid, and lamotrigine in healthy participants.

Primary outcomes

  • Maximum observed plasma concentration (Cmax)
  • Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
  • Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered